Harnessing novel technologies for precision medicine in pediatric diffuse midline glioma
01.03.2021 – 28.02.2026
Summary
Scientific abstract
Diffuse midline glioma (DMG) is a deadly cancer affecting children most commonly under the age of 10 years. DMG has a median survival of only 9-11 months and over 90% of children diagnosed with DMG will die within two years of diagnosis. Technological advancements, surgical/upfront biopsies, and cost-effective data generation platforms have resulted in the discovery of some of the molecular disease drivers. We and others ha...
Show more
Persons
Applicants
- Javad Nazarian, Abteilung Onkologie Universitäts-Kinderspital Zürich, Switzerland
- Sebastian Waszak, Laboratory of Computational Neuro-Oncology ISREC / School of Life Sciences Ecole Polytechnique Fédérale de Lausanne, Switzerland
- Mehmet Yanik, Neurotechnology Dept. of Inf.techno.u.Elektrotechnik ETHZ, Switzerland
Employees
- Mehdi Aghilibehnam
- Gizem Aydemir
- Nancy Saana Banono
- Carmelo Covato
- Katherine Genevieve Delevaux
- Noemi Favro
- Solène Fernandez
- Paul Johnson, Institut für Neuroinformatik Universität Zürich und ETH Zürich, Switzerland
- Anne Martina Kraus
- Bettina Kritzer
- Sandra Laternser
- MEHMET SIRIN ÖZDAS
Project partners
- Adriano Aguzzi, Institut für Neuropathologie Departement für Pathologie Universitätsspital Zürich, Switzerland
- Stephan Neuhauss, Institut für Molekulare Biologie Universität Zürich, Switzerland
- Pan Pantziarka, Anticancer Fund, Belgium
Disciplines and keywords
mySNF disciplines (provided by researchers): Interdisciplinary, Mechanical Engineering, Other disciplines of Engineering Sciences, Genetics, Experimental Cancer Research
Fields of research (mapped from mySNF Disciplines): n/a, Engineering, Genetics, Oncology and carcinogenesis, Mechanical engineering
Keywords: Neuronal network , Pediatric cancer, Diffuse midline glioma , metabolism , drug pathways , Bioinformatics, DIPG, DMG